SUDA Pharmaceuticals Ltd (SUDA), based in Australia and the US, is a world leader in reformulating and delivering medication through the oral mucosa.
Patients typically take medication as pills, tablets or capsules yet less than 25% of the medication is absorbed into the bloodstream.
SUDA can increase the bioavailability of administered medications, which means it increases the amount of the drug absorbed by the body so is able to increase the effect of that drug.
SUDA has increased bioavailability up to 95%. This is a major step forward in the evolution of drug delivery technology.
PERTH, AUSTRALIA – 9 December 2019: SUDA Pharmaceuticals Ltd (ASX:SUD), a leader in oromucosal drug delivery, is pleased to announce that it has entered into a feasibility agreement with SANOF…
SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that it has entered into a fully-funded, feasibility study and option agreement with Laboratorios Ordesa, …
Michael Baker joins SUDA Pharmaceuticals from the leading Australian life science fund, Bioscience Managers, where he was based from 2017. As an Investment Manager, he was responsible for deal sourc…